MARKET

SRRK

SRRK

Scholar Rock Holding
NASDAQ
30.67
-0.32
-1.03%
Pre Market: 31.01 +0.34 +1.11% 04:54 05/12 EDT
OPEN
31.10
PREV CLOSE
30.99
HIGH
31.88
LOW
30.44
VOLUME
4
TURNOVER
0
52 WEEK HIGH
46.98
52 WEEK LOW
6.76
MARKET CAP
2.91B
P/E (TTM)
-12.4326
1D
5D
1M
3M
1Y
5Y
1D
SCHOLAR ROCK TO HOST CONFERENCE CALL TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON MAY 14, 2025
Reuters · 4d ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 5d ago
US High Growth Tech Stocks To Watch
Simply Wall St · 6d ago
Weekly Report: what happened at SRRK last week (0428-0502)?
Weekly Report · 6d ago
Why Scholar Rock Stock Took a Knock on Monday
The Motley Fool · 04/28 23:08
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Compass Therapeutics (CMPX)
TipRanks · 04/28 16:20
Scholar Rock Appoints David Hallal as New CEO
TipRanks · 04/28 12:53
Scholar Rock Names David Hallal Chief Executive Officer; Appoints New CFO And COO
NASDAQ · 04/28 11:33
More
About SRRK
More
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
Recently
Symbol
Price
%Change

Webull offers Scholar Rock Holding Corp stock information, including NASDAQ: SRRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRRK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRRK stock methods without spending real money on the virtual paper trading platform.